Novo Nordisk A/S (LTS:0QIU) Total Tax Payable : kr7,116 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Novo Nordisk A/S Total Tax Payable?

Novo Nordisk A/S's Total Tax Payable for the quarter that ended in Dec. 2023 was kr7,116 Mil.

Novo Nordisk A/S's quarterly Total Tax Payable increased from Jun. 2023 (kr9,617 Mil) to Sep. 2023 (kr12,297 Mil) but then declined from Sep. 2023 (kr12,297 Mil) to Dec. 2023 (kr7,116 Mil).

Novo Nordisk A/S's annual Total Tax Payable increased from Dec. 2021 (kr3,658 Mil) to Dec. 2022 (kr7,091 Mil) and increased from Dec. 2022 (kr7,091 Mil) to Dec. 2023 (kr7,116 Mil).

Novo Nordisk A/S Total Tax Payable Historical Data

The historical data trend for Novo Nordisk A/S's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Total Tax Payable Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

4,212.00

3,913.00

3,658.00

7,091.00

7,116.00

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Tax Payable	Get a 7-Day Free Trial															7,091.00	6,062.00	9,617.00	12,297.00	7,116.00

Novo Nordisk A/S Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Novo Nordisk A/S Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (LTS:0QIU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (LTS:0QIU) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (LTS:0QIU) Headlines

No Headlines